

#3



SEQUENCE LISTING

<110> Gillies, Stephen  
Burger, Christa  
Lo, Kin-Ming

<120> Enhancing the Circulating Half-Life of Antibody-Based Fusion Proteins

<130> LEX-011

<140> US 09/780,668

<141> 2001-02-09

<150> US 60/181,768

<151> 2000-02-11

<160> 35

<170> PatentIn version 3.0

<210> 1

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Ig-IL-2 junction sequence

<400> 1

Ser Pro Gly Lys Ala Pro Thr

1 5

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Ig C-terminal sequence

<400> 2

Ser Pro Gly Lys

1

<210> 3

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> human gamma-1 heavy chain gene with a silent mutation

<400> 3  
 tccccgggta aa 12

<210> 4  
 <211> 42  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> 5' oligonucleotide with a Lys to Ala substitution

<400> 4  
 ccgggtgcag cacctacttc aagttctaca aagaaaacac ag 42

<210> 5  
 <211> 38  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> 3' oligonucleotide with a Lys to Ala substitution

<400> 5  
 ctgtgttttc tttgtagaac ttgaagtagg tgctgcac 38

<210> 6  
 <211> 42  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> 5' oligonucleotide with a Lys to Arg substitution

<400> 6  
 ccgggtaggg cgccaacttc aagttctaca aagaaaacac ag 42

<210> 7  
 <211> 38  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> 3' oligonucleotide with a Lys to Arg substitution

<400> 7  
 ctgtgttttc tttgtagaac ttgaagttgg cgccctac 38

<210> 8  
 <211> 39  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> 5' oligonucleotide with a Lys deletion  
  
 <400> 8  
 ccgggtgcac ctacttcaag ttctacaaag aaaacacag 39  
  
 <210> 9  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> 3' nucleotide with a Lys deletion  
  
 <400> 9  
 ctgtgttttc tttgtagaac ttgaagtagg tgcac 35  
  
 <210> 10  
 <211> 42  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> 5' oligonucleotide with a Lys to Gly substitution  
  
 <400> 10  
 ccgggtgggg cccctacttc aagttctaca aagaaaacac ag 42  
  
 <210> 11  
 <211> 38  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> 3' oligonucleotide with a Lys to Gly substitution  
  
 <400> 11  
 ctgtgttttc tttgtagaac ttgaagtagg ggccccac 38  
  
 <210> 12  
 <211> 42  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> 5' oligonucleotide with a Lys to Leu substitution  
  
 <400> 12  
 ccgggtctgg cgccaacttc aagttctaca aagaaaacac ag 42  
  
 <210> 13  
 <211> 38  
 <212> DNA

<213> Artificial Sequence  
 <220>  
 <223> 3' oligonucleotide with a Lys to Leu substitution  
 <400> 13  
 ctgtgttttc tttgtagaac ttgaagttgg cgccagac 38  
 <210> 14  
 <211> 48  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> 5' oligonucleotide with a Lys to AlaAlaAla substitution  
 <400> 14  
 ccgggtgcag cagctgcccc aacttcaagt tctacaaaga aaacacag 48  
 <210> 15  
 <211> 44  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> 3' oligonucleotide with a Lys to AlaAlaAla substitution  
 <400> 15  
 ctgtgttttc tttgtagaac ttgaagttgg ggcagctgct gcac 44  
 <210> 16  
 <211> 42  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> 5' oligonucleotide with a Lys to Cys substitution  
 <400> 16  
 ccgggttgcg caccaacttc aagttctaca aagaaaacac ag 42  
 <210> 17  
 <211> 38  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> 3' oligonucleotide with a Lys to Cys substitution  
 <400> 17  
 ctgtgttttc tttgtagaac ttgaagttgg tgcgcaac 38

<210> 18  
 <211> 42  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> 5' oligonucleotide with a Lys to Asp substitution  
  
 <400> 18  
 ccgggtgacg caccaacttc aagttctaca aagaaaacac ag 42  
  
 <210> 19  
 <211> 38  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> 3' oligonucleotide with a Lys to Asp substitution  
  
 <400> 19  
 ctgtgttttc ttgtagaac ttgaagttgg tgcgtcac 38  
  
 <210> 20  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> sequence at the antibody-IL2 gene fusion after linker ligation  
  
 <400> 20  
 cccggcatgc gggggtaaa 19  
  
 <210> 21  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> sequence at antibody-IL2 fusion junction  
  
 <400> 21  
  
 Pro Ala Cys Gly Gly Leu  
 1 5  
  
 <210> 22  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> 5' linker sequence  
  
 <400> 22

gggttcagga tccggagg

18

<210> 23  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> 3' linker sequence

<400> 23  
cctccggatc ctgaaccc

18

<210> 24  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> sequence at fusion junction

<400> 24

Pro Gly Ser Gly Ser Gly Gly Gly Lys  
1 5

<210> 25  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> 5' oligonucleotide with linker

<400> 25  
gggttcaggc tctggatcag ggtccggatc cgg

33

<210> 26  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> 3' oligonucleotide with linker

<400> 26  
ccggatccgg accctgatcc agagcctgaa ccc

33

<210> 27  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> sequence at fusion junction after linker insertion

<400> 27

Pro Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Gly Lys  
1 5 10

<210> 28  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> 5' oligonucleotide with a Pro to Ala substitution

<400> 28  
cgcagaagag cctctccctg tccgc 25

<210> 29  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> 3' oligonucleotide with a Pro to Ala substitution

<400> 29  
gcggacaggg agaggctctt ct 22

<210> 30  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> 5' oligonucleotide with a Pro to Leu substitution

<400> 30  
cgcagaagag cctctccctg tccct 25

<210> 31  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> 3' oligonucleotide with a Pro to Leu substitution

<400> 31  
agggacaggg agaggctctt ct 22

<210> 32  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> 5' oligonucleotide with a Pro to Gly substitution

<400> 32  
cgcagaagag cctctccctg tccgg

25

<210> 33  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> 3' oligonucleotide with a Pro to Gly substitution

<400> 33  
ccggacaggg agaggctctt ct

22

<210> 34  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Ig-TNF junction sequence

<400> 34

Ser Pro Gly Lys Val Arg Ser Ser Ser  
1 5

<210> 35  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Ig-(deleted Lys)-TNF fusion sequence

<400> 35

Ser Pro Gly Val Arg Ser Ser Ser  
1 5